人多能干细胞衍生心肌细胞的冷冻保存：策略、挑战与未来方向
Cryopreservation of Human Pluripotent Stem Cell-Derived Cardiomyocytes: Strategies, Challenges, and Future Directions.
作者信息
Preininger Marcela K, Singh Monalisa, Xu Chunhui
机构信息
Division of Pediatric Cardiology, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, 2015 Uppergate Drive, Atlanta, GA, 30322, USA.
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA.
出版信息
Adv Exp Med Biol. 2016;951:123-135. doi: 10.1007/978-3-319-45457-3_10.
Abstract
In recent years, human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) have emerged as a vital cell source for in vitro modeling of genetic cardiovascular disorders, drug screening, and in vivo cardiac regeneration research. Looking forward, the ability to efficiently cryopreserve hPSC-CMs without compromising their normal biochemical and physiologic functions will dramatically facilitate their various biomedical applications. Although working protocols for freezing, storing, and thawing hPSC-CMs have been established, the question remains as to whether they are optimal. In this chapter, we discuss our current understanding of cryopreservation appertaining to hPSC-CMs, and proffer key questions regarding the mechanical, contractile, and regenerative properties of cryopreserved hPSC-CMs.
摘要
近年来，人多能干细胞衍生的心肌细胞（hPSC-CMs）已成为用于遗传性心血管疾病体外建模、药物筛选及体内心脏再生研究的重要细胞来源。展望未来，能够在不损害其正常生化和生理功能的前提下高效冷冻保存hPSC-CMs，将极大地促进其在各种生物医学领域的应用。尽管已经建立了hPSC-CMs冷冻、储存和解冻的操作方案，但这些方案是否最优仍有待探讨。在本章中，我们讨论了目前对hPSC-CMs冷冻保存的认识，并提出了有关冷冻保存的hPSC-CMs的力学、收缩和再生特性的关键问题。
相似文献
1
Cryopreservation of Human Pluripotent Stem Cell-Derived Cardiomyocytes: Strategies, Challenges, and Future Directions.
Adv Exp Med Biol. 2016;951:123-135. doi: 10.1007/978-3-319-45457-3_10.
2
Effective Hypothermic Storage of Human Pluripotent Stem Cell-Derived Cardiomyocytes Compatible With Global Distribution of Cells for Clinical Applications and Toxicology Testing.
Stem Cells Transl Med. 2016 May;5(5):658-69. doi: 10.5966/sctm.2015-0238. Epub 2016 Mar 29.
3
Simple Workflow and Comparison of Media for hPSC-Cardiomyocyte Cryopreservation and Recovery.
Curr Protoc Stem Cell Biol. 2020 Dec;55(1):e125. doi: 10.1002/cpsc.125.
4
Slow Cooling Cryopreservation Optimized to Human Pluripotent Stem Cells.
Adv Exp Med Biol. 2016;951:57-65. doi: 10.1007/978-3-319-45457-3_5.
5
Maturation of Pluripotent Stem Cell-Derived Cardiomyocytes: a Critical Step for Drug Development and Cell Therapy.
J Cardiovasc Transl Res. 2018 Oct;11(5):375-392. doi: 10.1007/s12265-018-9801-5. Epub 2018 Mar 19.
6
Pluripotent stem cell-based cardiac regenerative therapy for heart failure.
J Mol Cell Cardiol. 2024 Feb;187:90-100. doi: 10.1016/j.yjmcc.2023.12.001. Epub 2024 Feb 6.
7
Functional improvement and maturation of human cardiomyocytes derived from human pluripotent stem cells by barbaloin preconditioning.
Acta Biochim Biophys Sin (Shanghai). 2019 Sep 6;51(10):1041-1048. doi: 10.1093/abbs/gmz090.
8
Current Strategies and Challenges for Purification of Cardiomyocytes Derived from Human Pluripotent Stem Cells.
Theranostics. 2017 May 17;7(7):2067-2077. doi: 10.7150/thno.19427. eCollection 2017.
9
Physical developmental cues for the maturation of human pluripotent stem cell-derived cardiomyocytes.
Stem Cell Res Ther. 2014 Oct 20;5(5):117. doi: 10.1186/scrt507.
10
Cryopreservation of Hair-Follicle Associated Pluripotent (HAP) Stem Cells Maintains Differentiation and Hair-Growth Potential.
Adv Exp Med Biol. 2016;951:191-198. doi: 10.1007/978-3-319-45457-3_16.
引用本文的文献
1
Biomanufacturing in low Earth orbit: A paradigm shift.
Stem Cell Reports. 2025 Jul 8;20(7):102536. doi: 10.1016/j.stemcr.2025.102536. Epub 2025 Jun 19.
2
DMSO-free cryopreservation of hiPSC-derived cardiomyocytes: low temperature characterization and protocol development.
Stem Cell Res Ther. 2025 Jun 10;16(1):301. doi: 10.1186/s13287-025-04384-5.
3
DMSO-free cryopreservation of hiPSC-derived cardiomyocytes: Low temperature characterization and protocol development.
Res Sq. 2025 Apr 14:rs.3.rs-5183739. doi: 10.21203/rs.3.rs-5183739/v1.
4
Hypothermic and cryogenic preservation of cardiac tissue-engineered constructs.
Biomater Sci. 2024 Jul 23;12(15):3866-3881. doi: 10.1039/d3bm01908j.
5
Standardized production of hPSC-derived cardiomyocyte aggregates in stirred spinner flasks.
Nat Protoc. 2024 Jul;19(7):1911-1939. doi: 10.1038/s41596-024-00976-2. Epub 2024 Mar 28.
6
Systematic cryopreservation study of cardiac myoblasts in suspension.
PLoS One. 2024 Mar 6;19(3):e0295131. doi: 10.1371/journal.pone.0295131. eCollection 2024.
7
Development of a novel ex vivo organ culture system to improve preservation methods of regenerative tissues.
Sci Rep. 2023 Feb 27;13(1):3354. doi: 10.1038/s41598-023-29629-2.
8
A Roadmap to Cardiac Tissue-Engineered Construct Preservation: Insights from Cells, Tissues, and Organs.
Adv Mater. 2021 Jul;33(27):e2008517. doi: 10.1002/adma.202008517. Epub 2021 May 28.
9
Novel test strategies for in vitro seizure liability assessment.
Expert Opin Drug Metab Toxicol. 2021 Aug;17(8):923-936. doi: 10.1080/17425255.2021.1876026. Epub 2021 Feb 17.
10
Effects of Cryopreservation on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Assessing Drug Safety Response Profiles.
Stem Cell Reports. 2021 Jan 12;16(1):168-181. doi: 10.1016/j.stemcr.2020.11.010. Epub 2020 Dec 17.
本文引用的文献
1
Cardiac tissue engineering using human stem cell-derived cardiomyocytes for disease modeling and drug discovery.
Drug Discov Today Dis Models. 2012 Winter;9(4):e219-e227. doi: 10.1016/j.ddmod.2012.11.001. Epub 2012 Dec 21.
2
Engineered human pluripotent stem cell-derived cardiac cells and tissues for electrophysiological studies.
Drug Discov Today Dis Models. 2012 Winter;9(4):e209-e217. doi: 10.1016/j.ddmod.2012.06.002.
3
Effective Hypothermic Storage of Human Pluripotent Stem Cell-Derived Cardiomyocytes Compatible With Global Distribution of Cells for Clinical Applications and Toxicology Testing.
Stem Cells Transl Med. 2016 May;5(5):658-69. doi: 10.5966/sctm.2015-0238. Epub 2016 Mar 29.
4
Induced pluripotent stem cells: at the heart of cardiovascular precision medicine.
Nat Rev Cardiol. 2016 Jun;13(6):333-49. doi: 10.1038/nrcardio.2016.36. Epub 2016 Mar 24.
5
Comparison of Magnetic Resonance Imaging and Serum Biomarkers for Detection of Human Pluripotent Stem Cell-Derived Teratomas.
Stem Cell Reports. 2016 Feb 9;6(2):176-87. doi: 10.1016/j.stemcr.2015.12.008. Epub 2016 Jan 14.
6
Development of a scalable suspension culture for cardiac differentiation from human pluripotent stem cells.
Stem Cell Res. 2015 Sep;15(2):365-75. doi: 10.1016/j.scr.2015.08.002. Epub 2015 Aug 13.
7
Expansion and patterning of cardiovascular progenitors derived from human pluripotent stem cells.
Nat Biotechnol. 2015 Sep;33(9):970-9. doi: 10.1038/nbt.3271. Epub 2015 Jul 20.
8
Enhanced Electrical Integration of Engineered Human Myocardium via Intramyocardial versus Epicardial Delivery in Infarcted Rat Hearts.
PLoS One. 2015 Jul 10;10(7):e0131446. doi: 10.1371/journal.pone.0131446. eCollection 2015.
9
A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients With Ischemic or Nonischemic Heart Failure.
Circ Res. 2015 Aug 28;117(6):576-84. doi: 10.1161/CIRCRESAHA.115.306332. Epub 2015 Jul 6.
10
Comparable calcium handling of human iPSC-derived cardiomyocytes generated by multiple laboratories.
J Mol Cell Cardiol. 2015 Aug;85:79-88. doi: 10.1016/j.yjmcc.2015.05.003. Epub 2015 May 14.
Zotero 插件